Payment overview · 2025
General Payments
$902.29
41 reported records · 15 companies
Healthcare provider profile · identity verified
William M Rudy, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · BERKLEY, MI · NPI 1790797207
Verified facts
What the public records show
CMS Open Payments records show William M Rudy, D.O. received $902.29 in general payments during 2025 across 41 reported records.
Novo Nordisk Inc accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $196.78 | 21.8% | 8 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $146.19 | 16.2% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $102.57 | 11.4% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $90.76 | 10.1% | 5 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $52.37 | 5.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $44.98 | 5.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.65 | 5.0% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $42.22 | 4.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.65 | 4.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $35.21 | 3.9% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.96 | 3.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.41 | 2.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.71 | 2.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.56 | 2.1% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.27 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $902.29 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $178.76 | 7 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $146.19 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $82.09 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $70.46 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $70.46 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $54.62 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $52.37 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $44.98 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $44.65 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $42.22 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $36.65 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $35.21 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $25.53 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| ALVESCO Normalized: alvesco |
Drug | Azurity Pharmaceuticals, Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 313 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 184 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 140 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 133 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 126 | 47 |
| Metformin Hcl | Metformin Hcl | 104 | 34 |
| Lisinopril | Lisinopril | 95 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 94 | 33 |
| Furosemide | Furosemide | 89 | 35 |
| Losartan Potassium | Losartan Potassium | 88 | 28 |
| Eliquis | Apixaban | 83 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 30 |
| Alprazolam | Alprazolam | 73 | 14 |
| Allopurinol | Allopurinol | 69 | 29 |
| Omeprazole | Omeprazole | 67 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 67 | 26 |
| Meloxicam | Meloxicam | 66 | 27 |
| Carvedilol | Carvedilol | 63 | 24 |
| Pregabalin | Pregabalin | 62 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 24 |
| Gabapentin | Gabapentin | 50 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 21 |
| Xarelto | Rivaroxaban | 47 | 11 |
| Levetiracetam | Levetiracetam | 46 | suppressed |
| Prednisone | Prednisone | 44 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 21 |
| Ezetimibe | Ezetimibe | 39 | 14 |
| Simvastatin | Simvastatin | 38 | 16 |
| Jardiance | Empagliflozin | 37 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 37 | 17 |
| Valsartan | Valsartan | 37 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 13 |
| Potassium Chloride | Potassium Chloride | 36 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | 13 |
| Nifedipine Er | Nifedipine | 34 | 14 |
| Famotidine | Famotidine | 32 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 11 |
| Diazepam | Diazepam | 31 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | 11 |
| Sertraline Hcl | Sertraline Hcl | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | 14 |
| Ozempic | Semaglutide | 27 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 20 |
| Lorazepam | Lorazepam | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 16 |
| Finasteride | Finasteride | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 14 |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $902.29 · 41 records | Novo Nordisk Inc | AIRSUPRA, ALVESCO, AZMIRO, BREZTRI, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, Kerendia, Korlym, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, Tymlos, ULTOMIRIS, VERQUVO, VOQUEZNA, Wegovy, YUPELRI, ZENPEP | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error